Strategies to advance translational research into brain barriers.
There is a paucity of therapies for most neurological disorders--from rare lysosomal storage diseases to major public health concerns such as stroke and Alzheimer's disease. Advances in the targeting of drugs to the CNS are essential for the future success of neurotherapeutics; however, the delivery of many potentially therapeutic and diagnostic compounds to specific areas of the brain is restricted by the blood-brain barrier, the blood-CSF barrier, or other specialised CNS barriers. These brain barriers are now recognised as a major obstacle to the treatment of most brain disorders. The challenge to deliver therapies to the CNS is formidable, and the solution will require concerted international efforts among academia, government, and industry. At a recent meeting of expert panels, essential and high-priority recommendations to propel brain barrier research forward in six topical areas were developed and these recommendations are presented here.
Neuwelt
Edward
E
Oregon Health and Science University, Department of Neurology, Veterans Administration Medical Center, Portland, OR, USA. neuelte@ohsu.edu
Abbott
N Joan
NJ
Abrey
Lauren
L
Banks
William A
WA
Blakley
Brian
B
Davis
Thomas
T
Engelhardt
Britta
B
Grammas
Paula
P
Nedergaard
Maiken
M
Nutt
John
J
Pardridge
William
W
Rosenberg
Gary A
GA
Smith
Quentin
Q
Drewes
Lester R
LR
D001692:Biological Transport; D035843:Biomedical Research; D001812:Blood-Brain Barrier / Q000502:physiology*; D001921:Brain / Q000187:drug effects; D001927:Brain Diseases / Q000188:drug therapy; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D008954:Models, Biological